Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Molecular Profile | BTK E41K |
Therapy | Vecabrutinib |
Indication/Tumor Type | Advanced Solid Tumor |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BTK E41K | Advanced Solid Tumor | predicted - sensitive | Vecabrutinib | Preclinical - Biochemical | Actionable | In a preclinical study, Vecabrutinib (SNS-062) inhibited Plcg2 activity in cells expressing BTK E41K in an in vitro assay (PMID: 34662393). | 34662393 |
PubMed Id | Reference Title | Details |
---|---|---|
(34662393) | Evaluation of vecabrutinib as a model for noncovalent BTK/ITK inhibition for treatment of chronic lymphocytic leukemia. | Full reference... |